Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 4/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12834710 | 0.83 | FFAR1 (0.37) | ACACBFFAR4FFAR1MEN1LMNA | |
| SCHEMBL13025992 | 0.83 | RAB9A (0.38) | ACACBFFAR4FFAR1MEN1KMT2A | |
| SCHEMBL12834165 | 0.80 | — | — | |
| SCHEMBL12834696 | 0.80 | KDM1A (0.37) | ACACBKDM1AGRM2FFAR4FFAR1 | |
| SCHEMBL13025734 | 0.76 | FFAR4 (0.36) | FFAR4 | |
| SCHEMBL22277205 | 0.76 | CTSL (0.35) | KDM1AGRM2FFAR4 | |
| SCHEMBL12834174 | 0.75 | FFAR4 (0.34) | FFAR4 | |
| SCHEMBL12834206 | 0.75 | — | — | |
| SCHEMBL22277520 | 0.75 | CTSL (0.34) | KDM1AFFAR4 | |
| SCHEMBL13025813 | 0.75 | PDE4D (0.38) | ACACBKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1731493-B1 | BENZENE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY | CHISSO CORP (JP) | 2011-03-23 | — | — | EP | disclosed |
| US-7838087-B2 | Benzene derivative, liquid crystal composition and liquid crystal display device | CHISSO CORPORATION (JP) | 2010-11-23 | — | — | US | disclosed |
| US-7838087-B2 | Benzene derivative, liquid crystal composition and liquid crystal display device | CHISSO CORPORATION (JP) | 2010-11-23 | — | — | US | disclosed |
| US-20070200092-A1 | Benzene Derivative, Liquid Crystal Composition And Liquid Crystal Display Device | JNC PETROCHEMICAL CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
| US-20070200092-A1 | Benzene Derivative, Liquid Crystal Composition And Liquid Crystal Display Device | JNC PETROCHEMICAL CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070200092-A1 | Benzene Derivative, Liquid Crystal Composition And Liquid Crystal Display Device | CCND2, YBX1, CNKSR1 | ACACB 2303/4885KDM1A 1661/4885GRM2 3839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.